Ocugen Stock News

Even if it isn't too late, Ocugen might not be a good investment.

During the last session, Ocugen Inc. (NASDAQ:OCGN)’s traded shares were 5.81 million, with the beta value of the company hitting 4.69. At the end of the trading day, the stock’s price was $2.65, reflecting an intraday loss of 0.00% or $0.0. The 52-week high for the OCGN share is $17.65, that puts it down -566.04 … The Ocugen Inc. (NASDAQ: OCGN) Stock Dropped -24.50% In A Single Month – Are There Any Hopes For A Gain? Read More »

The agency has declined to issue authorization for Ocugen's pediatric COVID-19 vaccine.

The agency has declined to issue authorization for Ocugen''s pediatric COVID-19 vaccine.

The agency has declined to issue authorization for Ocugen's pediatric COVID-19 vaccine.

Ocugen, Voyager Therapeutics, BioNTech, Regeneron and Gilead Sciences are included in this blog.

Ocugen Inc. (NASDAQ:OCGN) shares, rose in value on Wednesday, 03/09/22, with the stock price up by 8.61% to the previous day’s close as strong demand from buyers drove the stock to $2.65. Actively observing the price movement in the last trading, the stock closed the session at $2.44, falling within a range of $2.45 and … Ocugen Inc. (NASDAQ: OCGN) Is An Exciting Stock To Watch. Read More »

Ocugen, Inc. (NASDAQ:OCGN) with the stream of 8.61% also noticed, India Coupang, Inc. (NYSE:CPNG) encountered a rapid change of 8.98% in the last hour of Wednesday’s trading session. Ocugen, Inc. … The post Blustering Stock Grabbing Investor’s Attention: Ocugen, Inc. (NASDAQ:OCGN), Coupang, Inc. (NYSE:CPNG) appeared first on Stocks Equity .

Regulatory and other details from Ocugen (OCGN) as well as Voyager (VYGR) are a few key highlights from the biotech sector during the past week.

It's been more than a month since the company filed for Emergency Use Authorization of its COVID-19 vaccine.

MALVERN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cur

MALVERN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announces that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, Inc., will be presenting at the 34th Annual Roth Conference.

The company has hit several roadblocks along the coronavirus vaccine path.

MALVERN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure

The company has hit several roadblocks along the coronavirus vaccine path.